statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors considering a purchase of X4 Pharmaceuticals Inc (XFOR) shares, but tentative about paying the going market price of 1.40/share, might benefit from considering selling puts among the...

Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

X4 Pharmaceuticals (XFOR) has disclosed a new risk, in the Share Price & Shareholder Rights category. X4 Pharmaceuticals currently faces the risk o...

X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence

Q4 2023 X4 Pharmaceuticals Inc Earnings Call Transcript

Recap: X4 Pharmaceuticals Q4 Earnings

X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05...

X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05

Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 Additional Phase 2 clinical data and...

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Anticipation Builds for Potential U.S. Approval of MavorixaforRelated Stocks: XFOR...

X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results

X4 Pharmaceuticals's Earnings Outlook

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Watchers	3,201
52-Wk Low	$0.5723
52-Wk High	$2.58

Volume	1.07M
52-Wk High	$2.58
52-Wk Low	$0.5723

Period	Estimated	Reported	Surprise	Result
Q2'24	$0.01	--	--	N/A
Q1'24	-$0.15	-$0.26	-68.52%	MISSED
Q4'23	-$0.15	-$0.10	31.37%	BEAT
Q3'23	-$0.15	-$0.01	93.28%	BEAT
Q2'23	-$0.16	-$0.33	-103.42%	MISSED

XFOR X4 Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals